Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
7.91
+0.02 (0.25%)
Sep 16, 2026, 4:00 PM EDT - Market closed
Cartesian Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1.48 | 2.8 | 38.91 | 26 | 110.78 | 85.08 | |
Revenue Growth | 43.96% | -92.81% | 49.64% | -76.53% | 30.21% | - |
Cost of Revenue | 68.39 | 58.03 | 44.91 | 65.66 | 72.38 | 68.74 |
Gross Profit | -66.91 | -55.24 | -5.99 | -39.66 | 38.4 | 16.34 |
Selling, General & Admin | 31.75 | 31.47 | 29.53 | 34.75 | 23.86 | 20.94 |
Operating Expenses | 31.75 | 31.47 | 29.53 | 34.75 | 23.86 | 20.94 |
Operating Income | -98.66 | -86.71 | -35.52 | -74.41 | 14.54 | -4.6 |
Interest Expense | -0.85 | - | - | -2.83 | -3.03 | -2.84 |
Interest & Investment Income | 4.95 | 6.58 | 7.39 | 4.96 | 2.07 | 0.04 |
Currency Exchange Gain (Loss) | - | - | - | 0.04 | -0.02 | - |
Other Non Operating Income (Expenses) | -3.22 | 3.69 | -3.73 | -136.16 | 21.21 | -2.32 |
EBT Excluding Unusual Items | -97.78 | -76.44 | -31.86 | -208.4 | 34.77 | -9.72 |
Merger & Restructuring Charges | - | - | -0.8 | -11.3 | - | - |
Gain (Loss) on Sale of Investments | -2 | -2 | - | - | - | - |
Asset Writedown | -56.7 | -56.7 | -7.58 | -0.71 | - | - |
Other Unusual Items | -4.6 | -4.35 | -36.9 | -18.3 | - | - |
Pretax Income | -161.08 | -139.5 | -77.14 | -238.71 | 34.77 | -9.72 |
Income Tax Expense | -9.19 | -9.19 | 0.29 | -19 | -0.61 | 15.97 |
Net Income | -151.89 | -130.3 | -77.42 | -219.71 | 35.38 | -25.69 |
Preferred Dividends & Other Adjustments | - | - | - | 37.55 | - | - |
Net Income to Common | -151.89 | -130.3 | -77.42 | -257.26 | 35.38 | -25.69 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 27 | 26 | 17 | 5 | 5 | 4 |
Shares Outstanding (Diluted) | 27 | 26 | 17 | 5 | 5 | 4 |
Shares Change | 9.55% | 49.63% | 235.72% | 6.33% | 27.59% | - |
EPS (Basic) | -5.61 | -5.02 | -4.48 | -49.76 | 7.33 | -6.74 |
EPS (Diluted) | -5.61 | -5.02 | -4.48 | -49.76 | 2.98 | -6.74 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -78.61 | -79.4 | -32.77 | -51.37 | -32.83 | -61.47 |
Free Cash Flow Per Share | -2.90 | -3.06 | -1.89 | -9.94 | -6.75 | -16.13 |
Gross Margin | - | - | -15.40% | -152.50% | 34.66% | 19.21% |
Operating Margin | -6679.69% | -3099.93% | -91.27% | -286.13% | 13.12% | -5.40% |
Profit Margin | -10283.75% | -4658.63% | -198.97% | -989.31% | 31.94% | -30.19% |
Free Cash Flow Margin | -5322.41% | -2838.58% | -84.21% | -197.53% | -29.64% | -72.25% |
EBITDA | -96.05 | -83.75 | -34.37 | -73.56 | 15.83 | -3.35 |
EBITDA Margin | - | - | -88.32% | -282.89% | 14.29% | -3.93% |
D&A For EBITDA | 2.61 | 2.96 | 1.15 | 0.84 | 1.29 | 1.25 |
EBIT | -98.66 | -86.71 | -35.52 | -74.41 | 14.54 | -4.6 |
EBIT Margin | - | - | -91.27% | -286.13% | 13.12% | -5.40% |
Revenue as Reported | 1.48 | 2.8 | 38.91 | 26 | - | - |